LINAPRIDE M XR 500

About

LINAPRIDE M XR 500 is a combination medication for the treatment of type 2 diabetes mellitus, typically containing Linagliptin and Metformin Extended-Release 500mg. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by increasing the levels of active incretin hormones (GLP-1 and GIP). These hormones enhance glucose-dependent insulin secretion from pancreatic beta cells and suppress glucagon release from alpha cells, leading to improved blood glucose control. Metformin, in its extended-release form, reduces hepatic glucose production and improves insulin sensitivity over a prolonged period. This synergistic action helps to lower both fasting and post-meal blood sugar levels, providing comprehensive and sustained glycemic management for adults with type 2 diabetes, especially when diet and exercise alone are insufficient.

Uses

• Management of type 2 diabetes mellitus.
• As an adjunct to diet and exercise.
• To improve glycemic control in adults.
• When monotherapy with metformin is insufficient.

Directions For Use

Take orally once daily with the evening meal. Swallow the tablet whole; do not crush, chew, or break it, as this may affect its extended-release properties.

Benefits

• Provides sustained blood glucose control throughout the day.
• Low risk of hypoglycemia due to glucose-dependent action.
• Weight-neutral effect or modest weight loss.
• Improves both fasting and post-prandial glucose levels.
• Convenient once-daily dosing with extended release.
• Linagliptin does not require dose adjustment for renal impairment.

Side Effects

• Nausea and vomiting.
• Diarrhea.
• Abdominal discomfort or pain.
• Headache.
• Nasopharyngitis.
• Upper respiratory tract infection.
• Metallic taste in mouth.
• Lactic acidosis (rare, serious).
• Pancreatitis (rare, DPP-4 inhibitors).
• Joint pain.
• Vitamin B12 deficiency (long-term use).
• Skin reactions (e.g., urticaria).

Safety Measures

• Alcohol - Excessive alcohol intake should be avoided due to increased risk of lactic acidosis with metformin.
• Pregnancy - Not recommended during pregnancy; consult a healthcare professional for appropriate alternatives.
• Breastfeeding - Not advised as components may pass into breast milk; discuss with a doctor for safer options.
• Liver - Use with caution in patients with hepatic impairment; metformin may increase the risk of lactic acidosis.
• Kidney - Metformin is contraindicated in severe renal impairment. Linagliptin does not require dose adjustment for kidney function.
• Lung - Use with caution in severe respiratory conditions due to potential for hypoxia, which can increase lactic acidosis risk with metformin.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.